Design of Non-Standard Insulin Analogs for the Treatment of Diabetes Mellitus
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design of Non-Standard Insulin Analogs for the Treatment of Diabetes Mellitus
Authors
Keywords
-
Journal
Current Diabetes Reports
Volume 12, Issue 6, Pages 697-704
Publisher
Springer Nature
Online
2012-09-15
DOI
10.1007/s11892-012-0318-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database
- (2012) P. Blin et al. DIABETOLOGIA
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- -Helical element at the hormone-binding surface of the insulin receptor functions as a signaling element to activate its tyrosine kinase
- (2012) J. Whittaker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Closed-loop insulin delivery for treatment of type 1 diabetes
- (2011) Daniela Elleri et al. BMC Medicine
- Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps
- (2011) P. Schaepelynck et al. DIABETES & METABOLISM
- A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes: A randomized, controlled trial
- (2011) T. Heise et al. DIABETES CARE
- Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
- (2011) K. I. Birkeland et al. DIABETES CARE
- Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology
- (2011) Elsemiek E.C. Engwerda et al. DIABETES CARE
- Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis
- (2011) A. E. Pontiroli et al. DIABETES OBESITY & METABOLISM
- U-100, pH-Neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes
- (2011) L. Heinemann et al. DIABETES OBESITY & METABOLISM
- Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection
- (2011) Ronald J. Pettis et al. Diabetes Technology & Therapeutics
- Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study
- (2011) R. Ruiter et al. DIABETOLOGIA
- Use of Recombinant Human Hyaluronidase to Accelerate Rapid Insulin Analogue Absorption: Experience with Subcutaneous Injection and Continuous Infusion
- (2011) Daniel Vaughn et al. Endocrine Practice
- Glargine Promotes Proliferation of Breast Adenocarcinoma Cell Line MCF-7 via AKT Activation
- (2011) J.-A. Teng et al. HORMONE AND METABOLIC RESEARCH
- Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
- (2011) Bernard Zinman et al. LANCET
- The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes
- (2011) Marcus Lind et al. Primary Care Diabetes
- Rapid-Acting Insulin Analogues in Basal-Bolus Regimens in Type 1 Diabetes Mellitus
- (2010) Satish Garg et al. Endocrine Practice
- Beyond the Canonical 20 Amino Acids: Expanding the Genetic Lexicon
- (2010) Travis S. Young et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Supramolecular Protein Engineering
- (2010) Nelson B. Phillips et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Optimal Control of Blood Glucose: The Diabetic Patient or the Machine?
- (2010) L. Brown et al. Science Translational Medicine
- Insulin Glargine and NPH Insulin Increase to a Similar Degree Epithelial Cell Proliferation and Aberrant Crypt Foci Formation in Colons of Diabetic Mice
- (2010) Jutta M. Nagel et al. Hormones & Cancer
- Insulin Glulisine: An Evaluation of Its Pharmacodynamic Properties and Clinical Application
- (2009) Kristen L Helms et al. ANNALS OF PHARMACOTHERAPY
- Cost-effectiveness of insulin analogues for diabetes mellitus
- (2009) C. G. Cameron et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion
- (2009) Itamar Raz et al. CLINICAL THERAPEUTICS
- Insulin Glargine: a review 8 years after its introduction
- (2009) Stanislav Goykhman et al. EXPERT OPINION ON PHARMACOTHERAPY
- The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes
- (2008) Mike A. Baxter ACTA DIABETOLOGICA
- Is the use of insulin analogues cost-effective?
- (2008) Steven Leichter ADVANCES IN THERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started